Literature DB >> 8530242

Splenic arteriovenous fistula.

T E Brothers1, J C Stanley, G B Zelenock.   

Abstract

Splenic arteriovenous fistulas are uncommonly encountered, yet they can invoke serious pathophysiological consequences. Four patients treated for splenic fistulas at our institution over the last decade were combined with all previous case reports to produce the most extensive review yet reported, totalling 91 patients. Common etiologies included atherosclerotic aneurysm rupture (44%), congenital malformation (20%), and prior splenectomy (13%). The most frequent manifestation was gastrointestinal hemorrhage (48%), which was most prevalent with congenital fistulas (61% p < 0.05) or fistulas located proximally (54%, p < 0.005). Chronic portal hypertension that was usually characterized by preservation of hepatic function developed in 65%. Management included splenectomy (70%), fistula excision (59%), and occasionally required distal pancreatectomy (10%). Persistent portal hypertension necessitated operative portosystemic shunting in select cases (9%), with an overall 30 day operative mortality of 9%. While percutaneous embolization provided an additional therapeutic option in 4%, optimal management continues to include operative intervention.

Entities:  

Mesh:

Year:  1995        PMID: 8530242

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  3 in total

1.  Portal hypertension due to a splenic arteriovenous fistula: a case report.

Authors:  Mauricio Orrego; Hugo E Vargas; Vijayan Balan; Christopher Wells; M Edwyn Harrison; Joel Larson; Eric Huettl; Patrick T Liu
Journal:  Dig Dis Sci       Date:  2006-06       Impact factor: 3.199

2.  Idiopathic splenic arteriovenous fistula without splenic artery aneurysm.

Authors:  Shigeshi Ono; Hideaki Obara; Masayuki Shimoda; Yuko Kitagawa
Journal:  BMJ Case Rep       Date:  2015-04-22

3.  Coil Embolization of Spontaneous Splenic Arteriovenous Fistula for Treatment of Portal Hypertension.

Authors:  H Edward Garrett; Lamar Mack
Journal:  Am J Case Rep       Date:  2017-04-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.